The natriuretic peptide family consists of three
homologous members, atrial (ANP), B-type (BNP) and C-type
natriuretic peptides (CNP). These small peptides activate
specific membrane-bound guanylyl cyclase (GC) receptors (GC-A and
GC-B), thus modulating cellular functions via the intracellular
second messenger, cyclic GMP. Since the original discovery of
cardiac ANP more than two decades ago, the application of gene
targeting technology in mice has provided new valuable
information regarding the molecular physiology and diverse
biological functions of natriuretic peptides and their
receptors. The GC-A and ANP gene knockouts demonstrated that
this signalling system is not only essential in the maintenance
of normal blood pressure and volume, but also has local,
growth-moderating functions within the heart itself. Disruption
of the genes encoding BNP, CNP or the CNP-receptor, GC-B,
demonstrated that these “natriuretic peptides” are in fact
unlikely to physiologically regulate renal sodium excretion but
instead may exert important autocrine/paracrine cGMP-mediated
effects on cellular proliferation and differentiation in
different tissues. Notably, the intestinal peptide uroguanylin,
which activates a third guanylyl cyclase (GC-C), exerts
diuretic/natriuretic activity and links the intestine and kidney
in an endocrine way to modulate renal function in response to
oral salt load. Reviewed here is the physiology and biochemistry
of natriuretic peptides and their guanylyl cyclase receptors,
with special focus on the information gained to date from
targeted disruption of specific members of this peptide family,
their receptors, or effector molecules in the murine
system.